Xenon Achieves Milestone in Genentech Collaboration
News Sep 25, 2015
Xenon Pharmaceuticals Inc. has announced that the Company has achieved a milestone in its pain genetics discovery collaboration with Genentech, a member of the Roche Group, triggering a milestone payment.
Xenon and Genentech have successfully discovered and identified a novel pain target by leveraging Xenon's Extreme Genetics™ platform based on the study of rare phenotypes of individuals who have either an inability to perceive pain or have non-precipitated spontaneous severe pain.
"We are proud of our progress in our discovery collaboration with Genentech, which underscores the potential of our Extreme Genetics discovery platform and our ability to identify novel targets and pathways that may play a causal role in the sensation of pain," said Dr. Simon Pimstone, President and Chief Executive Officer of Xenon.
Dr. Pimstone continued, "There is a critical need for non-opioid alternatives for patients with chronic pain. We look forward to working further with Genentech to discover additional targets that could yield novel therapeutics."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.